文献速递腹部介入CT

VIPs在病毒性肝炎主导肝硬化中预测TIPS术后预后优于传统模型

VIPs outperforms established models for predicting post-TIPS prognosis in viral hepatitis-dominant cirrhosis.
PubMed 文献 · Eur J Radiol · 2026-01-13

本研究回顾性纳入247例接受TIPS的肝硬化患者(56.7%为病毒性肝炎),评估新型VIPs评分对肝移植免除生存的预测能力。VIPs在6、12、36、60个月的区分度均良好至中等,显著优于Child-Pugh、ALBI、FIPS、MOTS及脾体积模型,并在长期预测上优于MELD和MELD-Na。该评分在病毒性肝炎亚组中优势更为突出。

要点

  • VIPs对TIPS术后生存预测准确性优于传统模型,尤适用于病毒性肝炎肝硬化患者。
  • VIPs长期预测(36/60个月)能力显著超越MELD及MELD-Na评分。
  • VIPs在女性和静脉曲张出血患者中亦表现稳健,可辅助个体化决策。

核心结论

  • VIPs评分在病毒性肝炎为主的肝硬化队列中对TIPS术后移植免除生存表现出优于传统模型的预测准确性。
  • VIPs可作为指导个体化治疗决策的首选预后工具,尤其在病毒性肝炎患者中价值更高。

研究设计与样本

  • 单中心回顾性研究,纳入247例接受TIPS治疗的肝硬化患者,其中56.7%为病毒性肝炎病因。
  • 基于基线数据计算VIPs、MELD、MELD-Na、FIPS、Child-Pugh、ALBI、MOTS及脾体积模型共8个预后评分。
  • 主要终点为移植免除生存,评估时间点包括TIPS术后6、12、36及60个月。
  • 通过AUROC评估区分度,同时进行校准、解释力及决策曲线分析。

诊断标准与关键数值

  • VIPs在6个月时AUROC为0.794(95%CI 0.689–0.899),12个月为0.753(95%CI 0.649–0.858),36个月为0.721(95%CI 0.645–0.797),60个月为0.692(95%CI 0.617–0.767)。
  • 在病毒性肝炎亚组中,VIPs的AUROC范围在随访期内为0.699(95%CI 0.603–0.796)至0.822(95%CI 0.715–0.930)。
  • VIPs在所有时间点均显著优于Child-Pugh、ALBI、FIPS、MOTS及脾体积模型(均P<0.05),并在36/60个月长期预测中显著优于MELD和MELD-Na(均P<0.05)。
  • VIPs展现出最佳校准度(最低Brier评分范围0.076–0.217)及最高解释力(R²为0.121–0.142)。

临床应用与阅片要点

  • 日常阅片报告中可提示临床关注VIPs评分在病毒性肝炎肝硬化患者TIPS术后远期管理中的价值。
  • 对于女性和以静脉曲张出血为指征行TIPS的患者,VIPs的稳健表现可供风险分层参考。

局限性

  • 本研究为单中心回顾性设计,结果需在多中心前瞻性队列中验证。
  • 研究对象以病毒性肝炎肝硬化为主,VIPs在非病毒性肝炎肝硬化人群中的适用性尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) manages portal hypertension complications in cirrhosis, but predicting post-TIPS outcomes remains challenging, especially in viral hepatitis-dominated populations.

PURPOSE: To systematically evaluate the predictive performance of the novel Viral-Associated Index of Post-TIPS Score (VIPs) for post-TIPS prognosis. We also comprehensively compare it with six established clinical prognostic models and one imaging-based model (the spleen volume-based model, SvBM).

MATERIALS AND METHODS: We retrospectively analyzed 247 cirrhotic patients undergoing TIPS (56.7 % viral hepatitis). Baseline data calculated prognostic scores (VIPs, MELD, MELD-Na, FIPS, Child-Pugh, ALBI, MOTS, and SvBM). The primary endpoint was transplant-free survival (TFS). Discrimination was assessed by the area under the receiver operating characteristic curve (AUROC) at 6, 12, 36, and 60 months post-TIPS. Calibration (Brier score), explanatory power (R2), and decision curve analysis (DCA) were also evaluated.

RESULTS: VIPs demonstrated good-to-moderate discrimination for TFS, with AUROCs (95 % CI) of 0.794 (0.689-0.899), 0.753 (0.649-0.858), 0.721 (0.645-0.797), and 0.692 (0.617-0.767) at 6, 12, 36, and 60 months, respectively. This advantage was most pronounced in the viral hepatitis subgroup, with AUROCs ranging from 0.699 (0.603-0.796) to 0.822 (0.715-0.930) across follow-up. VIPs significantly outperformed Child-Pugh, ALBI, FIPS, MOTS and SvBM at all timepoints (all p < 0.05), and surpassed MELD and MELD-Na for long-term predictions (36/60 months, both p < 0.05). It also exhibited the best calibration (lowest Brier scores: 0.076-0.217) and the highest explanatory power (R2 = 0.121-0.142). Subgroup analyses further confirmed robust performance in females and patients with variceal bleeding.

CONCLUSIONS: VIPs demonstrates superior predictive accuracy for post-TIPS survival in a viral hepatitis-dominated cohort and may serve as a preferred prognostic tool to guide individualized decision-making.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Gao, Zhang, Li, et al. VIPs outperforms established models for predicting post-TIPS prognosis in viral hepatitis-dominant cirrhosis. Eur J Radiol. 2026. PMID: 41544552. doi:10.1016/j.ejrad.2026.112672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。